Skip to main content

Advertisement

SpringerLink
Log in

In vitro and in vivo Effects of Combination of Trastuzumab (Herceptin) and Tamoxifen in Breast Cancer

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Extensive interactions between estrogen receptor α (ERα) and HER2 signaling pathways have been described. Using BT-474 human breast cancer cells, we have previously shown that the combination of tamoxifen (TAM) and Herceptin results in strong synergistic growth inhibition, enhancement of G0–G1 cell cycle accumulation, inhibition of HER2 activity and a cytostatic effect without cell death. To further examine the underlying mechanism of synergy, we investigated the effect of this drug combination on ERα function and growth factor downstream signaling. TAM caused a small increase in ERα levels while Herceptin had no effect, and both drugs caused an increase in the level of Ser118-phosphorylated ERα. However, both TAM and Herceptin individually inhibited ERα transcriptional activity, although the combination did not have a greater effect than either single agent. Herceptin inhibited MAPK and Akt activity, while TAM had no effect on these either as a single agent or when added to Herceptin. Using a BALB/c athymic BT-474 in vivo xenograft model, the drug combination (Herceptin 0.3 mg/kg i.p. twice weekly, TAM 1.0 mg/mouse i.p. three times per week) showed a greater inhibition of tumor growth compared to either single agent. Tumor extracts and fixed sections were examined at the end of the treatment period for treatment-specific alterations: we noted a paradoxical proliferation-inducing effect of TAM that was reversed by the addition of Herceptin. Our results indicate that combined targeting of both peptide growth factor receptors and ERα represents a promising breast cancer treatment strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. R Schiff F Saw (2002) The importance of estrogen receptor in breast cancer P JR (Eds) Breast Cancer: Prognosis, Treatment, and Prevention Basel: Marcel Dekker, Inc. New York 149–186

    Google Scholar 

  2. RJ Pietras (2003) ArticleTitleInteractions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature Breast J 9 361–373 Occurrence Handle10.1046/j.1524-4741.2003.09510.x Occurrence Handle12968955

    Article  PubMed  Google Scholar 

  3. CK Osborne R Schiff (2003) ArticleTitleGrowth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer Breast 12 362–367 Occurrence Handle10.1016/S0960-9776(03)00137-1 Occurrence Handle14659106

    Article  PubMed  Google Scholar 

  4. R Schiff SA Massarweh J Shou L Bharwani SK Mohsin CK. Osborne (2004) ArticleTitleCross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance Clin Cancer Res 10 331S–336S Occurrence Handle14734488

    PubMed  Google Scholar 

  5. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire (1987) ArticleTitleHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177–182

    Google Scholar 

  6. C Wright B Angus S Nicholson JR Sainsbury J Cairns WJ Gullick P Kelly AL Harris CH Horne (1989) ArticleTitleExpression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer Cancer Res 49 2087–2090 Occurrence Handle2564806

    PubMed  Google Scholar 

  7. R Zeillinger F Kury K Czerwenka E Kubista G Sliutz W Knogler J Huber C Zielinski G Reiner R Jakesz et al. (1989) ArticleTitleHER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer Oncogene 4 109–114 Occurrence Handle2915900

    PubMed  Google Scholar 

  8. M Dowsett (2001) ArticleTitleOverexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer Endocr Related Cancer 8 191–195 Occurrence Handle10.1677/erc.0.0080191

    Article  Google Scholar 

  9. MP DiGiovanna (1999) Clinical significance of HER-2/neu overexpression: part II VT Vita ParticleDe SuffixJr. S Hellman SA Rosenberg (Eds) Principles and Practice of Oncology Lippincott Williams & Wilkins Cedar Knolls, NJ 1–14

    Google Scholar 

  10. MP DiGiovanna (1999) Clinical significance of HER-2/neu overexpression: part I VT DeVita SuffixJr. S Hellman SA Rosenberg (Eds) Principles and practice of oncology Lippincott Williams & Wilkins Cedar Knolls, NJ 1–10

    Google Scholar 

  11. JM Knowlden IR Hutcheson HE Jones T Madden JM Gee ME Harper D Barrow AE Wakeling RI Nicholson (2003) ArticleTitleElevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells Endocrinology 144 1032–1044 Occurrence Handle10.1210/en.2002-220620 Occurrence Handle12586780

    Article  PubMed  Google Scholar 

  12. H Kurokawa CL Arteaga (2001) ArticleTitleInhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer Clin Cancer Res 7 4436s–4442s Occurrence Handle11916237

    PubMed  Google Scholar 

  13. AE Wakeling RI Nicholson JM Gee (2001) ArticleTitleProspects for combining hormonal and nonhormonal growth factor inhibition Clin Cancer Res 7 4350s–4355s Occurrence Handle11916224

    PubMed  Google Scholar 

  14. LM Witters R Kumar VM Chinchilli A Lipton (1997) ArticleTitleEnhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody Breast Cancer Res Treat 42 1–5 Occurrence Handle10.1023/A:1005798224288 Occurrence Handle9116313

    Article  PubMed  Google Scholar 

  15. H Kunisue J Kurebayashi T Otsuki CK Tang M Kurosumi S Yamamoto K Tanaka H Doihara N Shimizu H Sonoo (2000) ArticleTitleAnti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2 Br J Cancer 82 46–51 Occurrence Handle10.1054/bjoc.1999.0875 Occurrence Handle10638965

    Article  PubMed  Google Scholar 

  16. CL Arteaga (2002) ArticleTitleEpidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7 IssueIDSuppl 4 31–39 Occurrence Handle12202786

    PubMed  Google Scholar 

  17. A Argiris CX Wang SG Whalen MP DiGiovanna (2004) ArticleTitleSynergistic interactions between tamoxifen and trastuzumab (Herceptin) Clin Cancer Res 10 1409–1420 Occurrence Handle14977844

    PubMed  Google Scholar 

  18. G Bunone PA Briand RJ Miksicek D Picard (1996) ArticleTitleActivation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation EMBO J 15 2174–2183 Occurrence Handle8641283

    PubMed  Google Scholar 

  19. S Kato H Endoh Y Masuhiro T Kitamoto S Uchiyama H Sasaki S Masushige Y Gotoh E Nishida H Kawashima et al. (1995) ArticleTitleActivation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase Science 270 1491–1494 Occurrence Handle7491495

    PubMed  Google Scholar 

  20. M Sun JE Paciga RI Feldman Z Yuan D Coppola YY Lu SA Shelley SV Nicosia JQ Cheng (2001) ArticleTitlePhosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K Cancer Res 61 5985–5991 Occurrence Handle11507039

    PubMed  Google Scholar 

  21. N Atanaskova VG Keshamouni JS Krueger JA Schwartz F Miller KB Reddy (2002) ArticleTitleMAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance Oncogene 21 4000–4008 Occurrence Handle10.1038/sj.onc.1205506 Occurrence Handle12037682

    Article  PubMed  Google Scholar 

  22. H Kurokawa AE Lenferink JF Simpson PI Pisacane MX Sliwkowski JT Forbes CL Arteaga (2000) ArticleTitleInhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells Cancer Res 60 5887–5894 Occurrence Handle11059787

    PubMed  Google Scholar 

  23. HH Zhao RE Herrera E Coronado-Heinsohn MC Yang JH Ludes-Meyers KJ Seybold-Tilson Z Nawaz D Yee FG Barr SG Diab PH Brown SA Fuqua CK Osborne (2001) ArticleTitleForkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions J Biol Chem 276 27907–27912 Occurrence Handle10.1074/jbc.M104278200 Occurrence Handle11353774

    Article  PubMed  Google Scholar 

  24. JF Robertson (1996) ArticleTitleOestrogen receptor: a stable phenotype in breast cancer Br J Cancer 73 5–12 Occurrence Handle8554983

    PubMed  Google Scholar 

  25. N Brunner TL Frandsen C Holst-Hansen M Bei EW Thompson AE Wakeling ME Lippman R Clarke (1993) ArticleTitleMCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780 Cancer Res 53 3229–3232 Occurrence Handle8324732

    PubMed  Google Scholar 

  26. AE Lykkesfeldt MW Madsen P Briand (1994) ArticleTitleAltered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1 Cancer Res 54 1587–1595 Occurrence Handle8137264

    PubMed  Google Scholar 

  27. A Howell J Robertson (1995) ArticleTitleResponse to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer Lancet 345 989–990 Occurrence Handle10.1016/S0140-6736(95)90739-4

    Article  Google Scholar 

  28. A Howell JF Robertson J Quaresma Albano A Aschermannova L Mauriac UR Kleeberg I Vergote B Erikstein A Webster C Morris (2002) ArticleTitleFulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 3396–3403 Occurrence Handle10.1200/JCO.2002.10.057 Occurrence Handle12177099

    Article  PubMed  Google Scholar 

  29. JX Zhang DC Labaree G Mor RB Hochberg (2004) ArticleTitleEstrogen to antiestrogen with a single methylene group resulting in an unusual steroidal selective estrogen receptor modulator J Clin Endocrinol Metab 89 3527–3535 Occurrence Handle10.1210/jc.2003-032005 Occurrence Handle15240642

    Article  PubMed  Google Scholar 

  30. DA Lannigan (2003) ArticleTitleEstrogen receptor phosphorylation Steroids 68 1–9 Occurrence Handle10.1016/S0039-128X(02)00110-1 Occurrence Handle12475718

    Article  PubMed  Google Scholar 

  31. D Chen T Riedl E Washbrook PE Pace RC Coombes JM Egly S Ali (2000) ArticleTitleActivation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7 Mol Cell 6 127–137 Occurrence Handle10.1016/S1097-2765(00)00014-9 Occurrence Handle10949034

    Article  PubMed  Google Scholar 

  32. PB Joel J Smith TW Sturgill TL Fisher DA Blenis J Lannigan (1998) ArticleTitlepp 90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167 Mol Cell Biol 18 1978–1984 Occurrence Handle9528769

    PubMed  Google Scholar 

  33. RA Campbell P Bhat-Nakshatri NM Patel D Constantinidou S Ali H Nakshatri (2001) ArticleTitlePhosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance J Biol Chem 276 9817–9824 Occurrence Handle10.1074/jbc.M010840200 Occurrence Handle11139588

    Article  PubMed  Google Scholar 

  34. GE Stoica TF Franke A Wellstein F Czubayko HJ List R Reiter E Morgan MB Martin A Stoica (2003) ArticleTitleEstradiol rapidly activates Akt via the ErbB2 signaling pathway Mol Endocrinol 17 818–830 Occurrence Handle10.1210/me.2002-0330 Occurrence Handle12554767

    Article  PubMed  Google Scholar 

  35. GE Stoica TF Franke M Moroni S Mueller E Morgan MC Iann AD Winder R Reiter A Wellstein MB Martin A Stoica (2003) ArticleTitleEffect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway Oncogene 22 7998–8011 Occurrence Handle10.1038/sj.onc.1206769 Occurrence Handle12970748

    Article  PubMed  Google Scholar 

  36. KA Power LU Thompson (2003) ArticleTitleLigand-induced regulation of ERalpha and ERbeta is indicative of human breast cancer cell proliferation Breast Cancer Res Treat 81 209–221 Occurrence Handle10.1023/A:1026114501364 Occurrence Handle14620916

    Article  PubMed  Google Scholar 

  37. H Liu ES Lee C Gajdos ST Pearce B Chen C Osipo J Loweth K McKian A Los Reyes ParticleDe L Wing VC Jordan (2003) ArticleTitleApoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo J Natl Cancer Inst 95 1586–1597 Occurrence Handle14600091

    PubMed  Google Scholar 

  38. S Kato Y Masuhiro M Watanabe Y Kobayashi KI Takeyama H Endoh J Yanagisawa (2000) ArticleTitleMolecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways Genes Cells 5 593–601 Occurrence Handle10.1046/j.1365-2443.2000.00354.x Occurrence Handle10947845

    Article  PubMed  Google Scholar 

  39. MC Rio JP Bellocq B Gairard UB Rasmussen A Krust C Koehl H Calderoli V Schiff R Renaud P Chambon (1987) ArticleTitleSpecific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2 Proc Natl Acad Sci USA 84 9243–9247 Occurrence Handle3321071

    PubMed  Google Scholar 

  40. SB Jakowlew R Breathnach JM Jeltsch P Masiakowski P Chambon (1984) ArticleTitleSequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7 Nucleic Acids Res 12 2861–2878 Occurrence Handle6324130

    PubMed  Google Scholar 

  41. AS Oh LA Lorant JN Holloway DL Miller FG Kern D El-Ashry (2001) ArticleTitleHyperactivation of MAPK induces loss of ERα expression in breast cancer cells Mol Endocrinol 15 1344–1359 Occurrence Handle10.1210/me.15.8.1344 Occurrence Handle11463858

    Article  PubMed  Google Scholar 

  42. JN Holloway S Murthy D El-Ashry (2004) ArticleTitleA cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-α down-regulation in breast cancer cells: The role of nuclear factor-kB Mol Endocrinol 18 1396–1410 Occurrence Handle10.1210/me.2004-0048 Occurrence Handle15056731

    Article  PubMed  Google Scholar 

  43. Z Yang CJ Barnes R Kumar (2004) ArticleTitleHuman epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor α in breast cancer cells Clin Cancer Res 10 3621–3628 Occurrence Handle15173068

    PubMed  Google Scholar 

  44. MJ Kelly ER Levin (2001) ArticleTitleRapid actions of plasma membrane estrogen receptors Trends Endocrinol Metab 12 152–156 Occurrence Handle10.1016/S1043-2760(01)00377-0 Occurrence Handle11295570

    Article  PubMed  Google Scholar 

  45. RX Song RA McPherson L Adam Y Bao M Shupnik R Kumar RJ Santen (2002) ArticleTitleLinkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation Mol Endocrinol 16 116–127 Occurrence Handle10.1210/me.16.1.116 Occurrence Handle11773443

    Article  PubMed  Google Scholar 

  46. G Castoria A Migliaccio A Bilancio M Domenico ParticleDi A Falco Particlede M Lombardi R Fiorentino L Varricchio MV Barone F Auricchio (2001) ArticleTitlePI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells EMBO J 20 6050–6059 Occurrence Handle10.1093/emboj/20.21.6050 Occurrence Handle11689445

    Article  PubMed  Google Scholar 

  47. DC Marquez RJ Pietras (2001) ArticleTitleMembrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells Oncogene 20 5420–5430 Occurrence Handle10.1038/sj.onc.1204729 Occurrence Handle11571639

    Article  PubMed  Google Scholar 

  48. H Kurokawa CL Arteaga (2003) ArticleTitleErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms Clin Cancer Res 9 511S–515S Occurrence Handle12538508

    PubMed  Google Scholar 

  49. FM Yakes W Chinratanalab CA Ritter W King S Seelig CL Arteaga (2002) ArticleTitleHerceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action Cancer Res 62 4132–4141 Occurrence Handle12124352

    PubMed  Google Scholar 

  50. PB Joel AM Traish DA Lannigan (1995) ArticleTitleEstradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor Mol Endocrinol 9 1041–1052 Occurrence Handle10.1210/me.9.8.1041 Occurrence Handle7476978

    Article  PubMed  Google Scholar 

  51. PB Joel AM Traish DA Lannigan (1998) ArticleTitleEstradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase J Biol Chem 273 13317–13323 Occurrence Handle10.1074/jbc.273.21.13317 Occurrence Handle9582378

    Article  PubMed  Google Scholar 

  52. BP Nicholson (2000) ArticleTitleOngoing and planned trials of hormonal therapy and trastuzumab Semin Oncol 27 33–37

    Google Scholar 

  53. SL Moulder FM Yakes SK Muthuswamy R Bianco JF Simpson CL Arteaga (2001) ArticleTitleEpidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo Cancer Res 61 8887–88895 Occurrence Handle11751413

    PubMed  Google Scholar 

  54. Bharwani L, Schiff R, Mohsin SK, Hilsenbeck SG, DiPietro M, Wakeling AE, Osborne CK: Inhibiting the EGFR/HER2 pathway with gefitinib and/or trastuzumab restores tamoxifen sensitivity in HER2-overexpressing tumors. 26th Annual San Antonio Breast Cancer Symposium, abstract 25, 2003

  55. Chang JC, Mohsin S, Weiss. H, Hilsenbeck. SG, Gutierrez. C, Lucci A, Kalidas M, Chamness GC, Osborne K, Elledge R: Induction of apoptosis without change in cell proliferation in primary breast cancers with neoadjuvant trastuzumab. 26th Annual San Antonio Breast Cancer Symposium, Breast Cancer Research and Treatment 82: pS13, 2003

  56. J Shou S Massarweh CK Osborne AE Wakeling S Ali H Weiss R Schiff (2004) ArticleTitleMechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J Natl Cancer Inst 96 926–935 Occurrence Handle15199112

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Internal Medicine (Section of Medical Oncology) and Pharmacology, Obstetrics and Gynecology, Pathology, and the Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, Room NSB288, 06510, New Haven, CT, USA

    Chun-Xia Wang, Debbie C. Koay, Andrea Edwards, Zhao Lu, Gil Mor, Idris T. Ocal & Michael P. DiGiovanna

Authors
  1. Chun-Xia Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Debbie C. Koay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhao Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gil Mor
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Idris T. Ocal
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Michael P. DiGiovanna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael P. DiGiovanna.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, CX., Koay, D.C., Edwards, A. et al. In vitro and in vivo Effects of Combination of Trastuzumab (Herceptin) and Tamoxifen in Breast Cancer. Breast Cancer Res Treat 92, 251–263 (2005). https://doi.org/10.1007/s10549-005-3375-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-005-3375-z

Keywords

Search

Navigation